HWHong Wang

Hong Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hong Wang has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Fan Yang

    From the Departments of Medicine (X.J., F.Y., H.T., D.L., J.K.R., R.E.R., W.D., X.Y., H.W.), Anesthesiology (R.M.B.), and Pharmacology (W.D.), Baylor College of Medicine, Houston, Tex; Michael E. DeBakey VA Medical Center (X.J., F.Y., H.T., D.L., R.E.R., W.D., H.W.), Houston, Tex; University of Pennsylvania School of Medicine (A.I.S.), Philadelphia, Pa

    5 shared publications
  • William Durante

    From the Departments of Medicine (X.J., F.Y., H.T., D.L., J.K.R., R.E.R., W.D., X.Y., H.W.), Anesthesiology (R.M.B.), and Pharmacology (W.D.), Baylor College of Medicine, Houston, Tex; Michael E. DeBakey VA Medical Center (X.J., F.Y., H.T., D.L., R.E.R., W.D., H.W.), Houston, Tex; University of Pennsylvania School of Medicine (A.I.S.), Philadelphia, Pa

    5 shared publications
  • Andrew I. Schafer

    From the Departments of Medicine (X.J., F.Y., H.T., D.L., J.K.R., R.E.R., W.D., X.Y., H.W.), Anesthesiology (R.M.B.), and Pharmacology (W.D.), Baylor College of Medicine, Houston, Tex; Michael E. DeBakey VA Medical Center (X.J., F.Y., H.T., D.L., R.E.R., W.D., H.W.), Houston, Tex; University of Pennsylvania School of Medicine (A.I.S.), Philadelphia, Pa

    4 shared publications
  • XiaoHua Jiang

    From the Departments of Medicine, Pharmacology, and Pathology, Baylor College of Medicine, Houston, TX; VA Medical Center, Houston, TX; and Mayo Clinic, Rochester, MN

    4 shared publications
  • Gary B. Chapman

    From the Departments of Medicine and Pharmacology, Baylor College of Medicine, Department of Bioengineering, Rice University, and VA Medical Center, Houston, TX; and Medicine/Cardiology, Albert Einstein College of Medicine, New York, NY

    2 shared publications
  • Andrew I Schafer

    1 shared publication

Latest Publications

  • Hyperhomocysteinemia inhibits post-injury reendothelialization in mice

    by H Tan, X Jiang, F Yang, Z Li, D Liao, J Trial, M Magera, W Durante, X Yang, H Wang

    Hyperhomocysteinemia (HHcy) is a risk factor for cardiovascular disease and has been reported to inhibit endothelial cell (EC) growth. Notwithstanding, precisely how HHcy regulates EC growth in vivo remains unknown. In this study, we established a mouse model of endothelial injury and reendothelialization and examined the role and mechanism of HHcy in endothelial repair. A mouse model of carotid artery air-dry endothelium denudation and reendothelialization was established and used to evaluate post-injury endothelial repair in mice with the gene deletion of cystathionine-beta-synthase (CBS). Moderate and severe HHcy were induced in CBS+/+ and CBS-/+ mice through a high-methionine diet. Post-injury reendothelialization, which correlated with increased post-injury neointima formation, was impaired in severe HHcy mice. To elucidate the underlying mechanism, we examined circulating endothelial progenitor cells (EPC) in HHcy mice and studied the effect of homocysteine (Hcy) on proliferation, migration, and adhesion of human umbilical vein endothelial cells (HUVEC). The peripheral EPC population was not significantly altered in HHcy mice. Hcy had a profound inhibitory effect on EC proliferation and migration at physiologically relevant concentrations and inhibited EC adhesion at concentrations of 200 microM and higher. We have established a convenient and accurate mouse model of carotid injury in which the reendothelialization process can be precisely quantified. In addition, we have observed impaired reendothelialization and increased neointimal formation in severe HHcy mice. The capacity of Hcy to inhibit proliferation and migration of EC may be responsible for impaired reendothelialization and contribute to arteriosclerosis in HHcy.


  • Hyperhomocystinemia Impairs Endothelial Function and eNOS Activity via PKC Activation

    by Xiaohua Jiang, Fan Yang, Hongmei Tan, Dan Liao, Robert M. Bryan, Jaspreet K. Randhawa, Rolando E. Rumbaut, William Durante, Andrew I. Schafer, Xiaofeng Yang, et al.

    Objective—A risk factor for cardiovascular disease, hyperhomocystinemia (HHcy), is associated with endothelial dysfunction. In this study, we examined the mechanistic role of HHcy in endothelial dysfunction.Methods and Results—Through the use of 2 functional models, aortic rings and intravital video microscopy of the cremaster, we found that arterial relaxation in response to the endothelium-dependent vessel relaxant, acetylcholine or the nitric oxide synthase (NOS) activator (A23187), was significantly impaired in cystathionine β-synthase null (CBS−/−) mice. However, the vascular smooth muscle cell (VSMC) response to the nitric oxide (NO) donor (SNAP) was preserved in CBS−/−mice. In addition, superoxide dismutase and catalase failed to restore endothelium-dependent vasodilatation. Endothelial nitric oxide synthase (eNOS) activity was significantly reduced in mouse aortic endothelial cells (MAECs) of CBS−/−mice, as well as in Hcy-treated mouse and human aortic endothelial cells (HAECs). Hcy-mediated eNOS inhibition—which was not rescued by adenoviral transduction of superoxide dismutase and glutathione peroxidase, or by tetrahydrobiopterin, sepiapterin, and arginine supplementations in MAEC—was associated with decreased protein expression and increased threonine 495 phosphorylation of eNOS in HAECs. Ultimately, a protein kinase C (PKC) inhibitor, GF109203X (GFX), reversed Hcy-mediated eNOS inactivation and threonine 495 phosphorylation in HAECs.Conclusions—These data suggest that HHcy impairs endothelial function and eNOS activity, primarily through PKC activation.


  • Hyperhomocysteinemia accelerates atherosclerosis in cystathionine β-synthase and apolipoprotein E double knock-out mice with and without dietary perturbation

    by Hong Wang, XiaoHua Jiang, Fan Yang, John W. Gaubatz, Lang Ma, Mark J. Magera, XiaoFeng Yang, Peter B. Berger, William Durante, Henry J. Pownall, et al.

    Although hyperhomocysteinemia is an independent risk factor for cardiovascular disease, a direct role for homocysteine (Hcy) in this disease remains to be shown. Whereas diet-induced hyperhomocysteinemia promotes atherosclerosis in animal models, the effects of Hcy on atherogenesis in the absence of dietary perturbations is not known. We have generated double knock-out mice with targeted deletions of the genes for apolipoprotein E (apoE) and cystathionine β-synthase (CBS), which converts Hcy to cystathionine. ApoE−/−/CBS−/− mice developed aortic lesions even in the absence of dietary manipulation; lesion area and lesion cholesteryl ester (CE) and triglyceride (TG) contents increased with animal age and plasma Hcy levels. Plasma total cholesterol was significantly increased, whereas high density lipoprotein (HDL) cholesterol and TG concentrations of apoE−/−/CBS−/− mice were decreased. Cholesterol esterification and activities of enzymes catalyzing CE or TG formation in the vessel wall and in peritoneal macrophages were not changed by hyperhomocysteinemia. However, uptake of human acetyl-LDL, but not native low density lipoprotein (LDL), by mouse peritoneal macrophages was higher in the presence of hyperhomocysteinemia. These results suggest that isolated hyperhomocysteinemia is atherogenic and alters hepatic and macrophage lipoprotein metabolism, in part, by enhancing uptake of modified LDL.


    • 1 February 2002
      • Vol. 99  (3) , 939-45

    Cyclin A transcriptional suppression is the major mechanism mediating homocysteine-induced endothelial cell growth inhibition.

    by Hong Wang, XiaoHua Jiang, Fan Yang, Gary B Chapman, William Durante, Nicholas E S Sibinga, Andrew I Schafer

    Previously, it was reported that homocysteine (Hcy) specifically inhibits the growth of endothelial cells (ECs), suppresses Ras/mitogen-activated protein (MAP) signaling, and arrests cell growth at the G(1)/S transition of the cell cycle. The present study investigated the molecular mechanisms underlying this cell-cycle effect. Results showed that clinically relevant concentrations (50 microM) of Hcy significantly inhibited the expression of cyclin A messenger RNA (mRNA) in ECs in a dose- and time-dependent manner. G(1)/S-associated molecules that might account for this block were not changed, because Hcy did not affect mRNA and protein expression of cyclin D1 and cyclin E. Cyclin D1- and E-associated kinase activities were unchanged. In contrast, cyclin A-associated kinase activity and CDK2 kinase activity were markedly suppressed. Nuclear run-on assay demonstrated that Hcy decreased the transcription rate of the cyclin A gene but had no effect on the half-life of cyclin A mRNA. In transient transfection experiments, Hcy significantly inhibited cyclin A promoter activity in endothelial cells, but not in vascular smooth muscle cells. Finally, adenovirus-transduced cyclin A expression restored EC growth inhibition and overcame the S phase block imposed by Hcy. Taken together, these findings indicate that cyclin A is a critical functional target of Hcy-mediated EC growth inhibition.


  • Open Access

    Cyclin A transcriptional suppression is the major mechanism mediating homocysteine-induced endothelial cell growth inhibition

    by Hong Wang, XiaoHua Jiang, Fan Yang, Gary B. Chapman, William Durante, Nicholas E. S. Sibinga, Andrew I. Schafer

    Previously, it was reported that homocysteine (Hcy) specifically inhibits the growth of endothelial cells (ECs), suppresses Ras/mitogen-activated protein (MAP) signaling, and arrests cell growth at the G1/S transition of the cell cycle. The present study investigated the molecular mechanisms underlying this cell-cycle effect. Results showed that clinically relevant concentrations (50 μM) of Hcy significantly inhibited the expression of cyclin A messenger RNA (mRNA) in ECs in a dose- and time-dependent manner. G1/S-associated molecules that might account for this block were not changed, because Hcy did not affect mRNA and protein expression of cyclin D1 and cyclin E. Cyclin D1- and E-associated kinase activities were unchanged. In contrast, cyclin A–associated kinase activity and CDK2 kinase activity were markedly suppressed. Nuclear run-on assay demonstrated that Hcy decreased the transcription rate of the cyclin A gene but had no effect on the half-life of cyclin A mRNA. In transient transfection experiments, Hcy significantly inhibited cyclin A promoter activity in endothelial cells, but not in vascular smooth muscle cells. Finally, adenovirus-transduced cyclin A expression restored EC growth inhibition and overcame the S phase block imposed by Hcy. Taken together, these findings indicate that cyclin A is a critical functional target of Hcy-mediated EC growth inhibition.


  • Open Access

    Cyclin A transcriptional suppression is the major mechanism mediating homocysteine-induced endothelial cell growth inhibition

    by Hong Wang, XiaoHua Jiang, Fan Yang, Gary B. Chapman, William Durante, Nicholas E. S. Sibinga, Andrew I. Schafer

    Previously, it was reported that homocysteine (Hcy) specifically inhibits the growth of endothelial cells (ECs), suppresses Ras/mitogen-activated protein (MAP) signaling, and arrests cell growth at the G1/S transition of the cell cycle. The present study investigated the molecular mechanisms underlying this cell-cycle effect. Results showed that clinically relevant concentrations (50 μM) of Hcy significantly inhibited the expression of cyclin A messenger RNA (mRNA) in ECs in a dose- and time-dependent manner. G1/S-associated molecules that might account for this block were not changed, because Hcy did not affect mRNA and protein expression of cyclin D1 and cyclin E. Cyclin D1- and E-associated kinase activities were unchanged. In contrast, cyclin A–associated kinase activity and CDK2 kinase activity were markedly suppressed. Nuclear run-on assay demonstrated that Hcy decreased the transcription rate of the cyclin A gene but had no effect on the half-life of cyclin A mRNA. In transient transfection experiments, Hcy significantly inhibited cyclin A promoter activity in endothelial cells, but not in vascular smooth muscle cells. Finally, adenovirus-transduced cyclin A expression restored EC growth inhibition and overcame the S phase block imposed by Hcy. Taken together, these findings indicate that cyclin A is a critical functional target of Hcy-mediated EC growth inhibition.